A look back at 2016 in *International Journal of Hematologic Oncology*

“It is exciting to see how our readership has grown in Asia, particularly in China, Japan and India. We look forward to seeing our global audience continue to expand as the journal grows within the oncology management community.”

Sebastian Dennis-Beron^{*1}

First draft submitted: 27 February 2017; Accepted for publication: 7 March 2017;
Published online: 18 May 2017

As the fifth volume of *International Journal of Hematologic Oncology* comes to a close, we would like to take the opportunity to provide our readers with a summary of some of the fantastic works we have published in the past volume, as well as highlight the growth and development of the journal over the last year.

We would first and foremost like to thank our valued editorial board, readers and contributors for all their support since our inception and of course over the last year, as the journal continues to mature. We continue to receive high-quality manuscripts from academics and clinicians from across the field of hematologic oncology, providing us with their expertise and perspectives on the field.

The editorial team anticipates seeing the journal continue to progress as we enter our sixth volume and over the course of 2017.

KEYWORDS

- hematologic cancer
- leukemia • lymphoma
- malignancies
- management • myeloma

Content highlights

At the time of writing (January 2017), the journal's most read article in 2016 was a review article by Yangqiu Li from Jinan University (Guangzhou, China), which delved into the clinical implications of T-cell immune suppression in patients with hematologic malignancies [1]. Li probed into the how T-cell immunosuppression, as a result of suppression due to either the malignancy itself or due to secondary immunosuppression by chemotherapy or stem cell transplantation, afflicted the patient. Li then further discussed how immunosuppression could be reversed by means of adoptive cell therapy or via inhibition of immune suppressors.

Another popular article in 2016 was an interview with Steven T Rosen from City of Hope National Medical Center (CA, USA), where Rosen discussed his career and highlighted some of his greatest achievements [2]. Rosen also discussed some of his current research, his thoughts on the field and how research focus can change depending on one's situation.

One of the most-read articles from our fifth issue was an interview with Francesco Lo-Coco based at University Tor Vergata (Rome, Italy); Lo-Coco disseminated the latest developments in the use of Trisenox[®] as a first-line treatment for Acute Promyelocytic Leukemia, following approval for use of the drug in Europe by the European Commission [3]. Lo-Coco provides his expert view on

¹Future Science Group, Unitec House, 2 Albert Place, London N31QB, UK

*Author for correspondence: s.dennis-beron@futuremedicine.com

the clinical trial outcomes that led to the drug's approval, as well as critically analyze the clinical trial.

Having been partnered to Altmetric as of 2015, to aid in visualizing the online impact of our published content, a special mention goes to the following article for having the highest Altmetric scores over *International Journal of Hematologic Oncology's* 5 years of publication.

- 'Management of multiple myelomas: the impact of ixazomib's approval in Canada', an interview with Donna Reece (Princess Margaret Cancer Centre, Toronto, Canada) [4].
- 'Targeting hypoxia in the leukemia microenvironment' from Benito *et al.* [5].
- 'Characterization and targeting of neoplastic stem cells in Ph+ chronic myeloid leukemia' by Arock *et al.* [6].

Oncology Central

In 2016, we solidified our partnership with the online platform Oncology Central, which we established at the end of 2015. Oncology Central is a free online resource that is designed exclusively for its medical professionals with an interest in oncology, aiming to deliver high-quality and relevant content in an accessible and innovative way [7]. Through Oncology Central, we endeavor to keep our increasing audience of approximately 5000 professionals up to date with the latest developments in cancer management and research with free access to the latest oncology news, opinion, peer-reviewed journal

articles and more exclusive content.

The partnership means that as well as featuring our content on the site, Oncology Central members have free access to all content published from across the Oncology Management journals published by Future Medicine (*Breast Cancer Management, CNS Oncology, Colorectal Cancer, Hepatic Oncology, International Journal of Endocrine Oncology, International Journal of Hematologic Oncology, Lung Cancer Management & Melanoma Management*).

If you would like to be a member of *Oncology Central* yourself, you will receive free access to timely content published in Oncology Central-partnered journals. Please feel free to contact us via email: oncology.management@futuremedicine.com.

Readership demographics

From our readership demographics, it is clear to see that our content has a truly global impact (Figure 1). It is interesting to note how the spread of our readers has progressed over the course of 2016; though the majority of our readers hail from Europe (42%), there is steady growth in our content being read in North America (28%) and Asia (20%). It is exciting to see how our readership has grown in Asia, particularly in China, Japan and India. We look forward to seeing our global audience continue to expand as the journal grows within the oncology management community.

Conclusion

With the fifth volume of *International Journal of Hematologic Oncology* coming to a close, we begin to look forward to the exciting developments in store for the journal scheduled in 2017. These developments include, though are not limited to, revisiting our aims and scopes, looking at different ways of engaging with the wider cancer management community, and potentially featuring novel and interesting article types that we hope can be of great value to the field.

We appreciate all feedback from the oncology community regarding the direction of our content such as 'hot topics' in the field and trends that you feel we should be covering as a management-focused journal.

We welcome unsolicited articles and proposals, and we would be more than willing to hear from you, particularly if you have any original research or case reports aimed specifically at the management of hematologic malignancies,

Figure 1. Readership demographics per continent for *International Journal of Hematologic Oncology* in 2016.

which we are actively aiming to feature in the journal moving forward.

A reminder that we are active on social media – do follow the journal on twitter (@fsgijh) for the latest news from across the field and for updates from the journal.

We very much look forward to future collaborations with you all as we enter volume 6. We hope *International of Journal of Hematologic Oncology* cements its position within the management community and continues to develop and flourish.

Financial & competing interests disclosure

S Dennis-Beron is an employee of Future Medicine Ltd. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

- 1 Li Y. T-cell immune suppression in patients with hematologic malignancies: clinical implications. *Int. J. Hematol. Oncol.* 3(4), 289–297 (2014).
- 2 Rosen ST. Interview: cancer-focused research. *Int. J. Hematol. Oncol.* 3(2), 109–111 (2014).
- 3 Lo-Coco F. Trisenox: a paradigm shift in APL therapy, an interview with Francesco Lo-Coco. *Int. J. Hematol. Oncol.* 5(3), 101–104 (2016).
- 4 Reece DE. Management of multiple myeloma: the impact of ixazomib's approval in Canada. *Int. J. Hematol. Oncol.* 5(3), 97–99 (2016).
- 5 Benito J, Zeng Z, Konopleva M, Wilson WR. Targeting hypoxia in the leukemia microenvironment. *Int. J. Hematol. Oncol.* 2(4), 279–288 (2013).
- 6 Arock M, Mahon FX, Valent P. Characterization and targeting of neoplastic stem cells in Ph+ chronic myeloid leukemia. *Int. J. Hematol. Oncol.* 4(4), 151–165 (2015).
- 7 Oncology Central website. www.oncology-central.com